ANI Pharmaceuticals Posts Record Quarter as Rare-Disease Drugs Power 29.6% Sales Jump

Management reaffirmed 2026 targets, signaling a mid-2026 build-out of its rare-disease commercial team.

Overview

Quarterly revenue reached $247.1 million, up 29.6% year over year, marking record full-year results.
Rare-disease sales rose 50.8% to $131.3 million, led by Cortrophin Gel at $111.4 million with broader prescribing that includes more than 15% of use for acute gout flares.
ILUVIEN contributed $19.8 million as improved reimbursement and access initiatives lifted uptake across approved indications.
Generics revenue increased 28.2% to $100.8 million, driven by a partnered launch that began in Q3 and additional 2025 product introductions.
Net income was $27.5 million after a prior-year loss, with adjusted EPS of $2.33 and adjusted EBITDA up 30.6% to $65.4 million; 2026 guidance was reaffirmed at $1.055–$1.115 billion in revenue and up to $290 million in adjusted EBITDA as shares rose to $77.15 and traded at $78.68 pre-market.